Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male Volunteers and Cystic Fibrosis Patients
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs Bovine lactoferrin/hypothiocyanite (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Alaxia
- 07 Jun 2017 Biomarkers information updated
- 11 May 2017 Planned number of patients changed from 66 to 124.
- 11 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.